News & Updates

Rimegepant effective in triptan-exposed migraine patients

26 Mar 2024

Rimegepant is effective for acute treatment of migraine in patients with a history of insufficient response to triptans and in current triptan users, a post-hoc analysis of three randomized, double-blind, multicentre phase III trials has shown.

Rimegepant effective in triptan-exposed migraine patients

26 Mar 2024

Management of adults with SMA: Practical considerations and treatment experiences

15 Feb 2024 by

Spinal muscular atrophy (SMA) is an inherited disorder that causes progressive muscle degeneration and weakness. Although there is no cure for SMA, emerging disease-modifying treatments can potentially change disease trajectory and substantially improve patients’ outcomes. At a local symposium, Professor Tim Hagenacker of the Department of Neurology, Essen University Hospital in Essen, Germany, shared his clinical experience and expertise in managing adults with SMA, with a focus on early treatment with an oral drug, risdiplam (Evyrsdi^®). Dr Shirley Pang of the Division of Neurology, Queen Mary Hospital, Hong Kong, reported preliminary data on treatment outcomes with risdiplam in Hong Kong.

Management of adults with SMA: Practical considerations and treatment experiences

15 Feb 2024

Fremanezumab effective in migraine prevention and depression management

15 Feb 2024 by

A holistic approach to migraine management involves taking into consideration patients’ psychiatric comorbidities and addressing the cumulative burden of both diseases to help improve overall treatment outcomes. At an industry-sponsored symposium during the 2023 International Headache Congress in Seoul, South Korea, experts in neurology stressed the importance of bridging the gap between psychiatry and neurology in migraine care by highlighting the role of the calcitonin gene–related peptide (CGRP) pathway monoclonal antibody (mAb), fremanezumab, in migraine prevention in patients with comorbid major depressive disorder (MDD).

Fremanezumab effective in migraine prevention and depression management

15 Feb 2024

Use of radioligand therapy in a patient with metastatic GEP-NET

08 Feb 2024 by

A 64-year-old male with good past health presented in March 2019 with 2 days’ history of abdominal pain, which subsided on its own.

Use of radioligand therapy in a patient with metastatic GEP-NET

08 Feb 2024

Use of low-dose edoxaban in a 99-year-old AF patient with comorbidities and comedications

22 Jan 2024 by

A 99-year-old Chinese female first presented in January 2022 with two episodes of sudden-onset transient left-sided weakness and dysarthria that resolved completely. At the age of 50 years, she was treated for pulmonary tuberculosis. She underwent resection of colon carcinoma at the age of 80 years and had remained in remission since.

Use of low-dose edoxaban in a 99-year-old AF patient with comorbidities and comedications

22 Jan 2024

Protecting adults against herpes zoster: Why it matters

25 Mar 2023

Herpes zoster occurs when the varicella zoster virus that lay dormant in the body after recovering from chickenpox reactivate later in life. Complications from herpes zoster can cause chronic, debilitating pain and disability. Three clinicians share why preventing herpes zoster matters for everyone.

Protecting adults against herpes zoster: Why it matters

25 Mar 2023

TTFields use in special GBM populations and potential combination with immunotherapy

14 Feb 2023 by

Glioblastoma multiforme (GBM) is the most common and aggressive brain tumour with a very poor prognosis. Tumour-treating fields (TTFields) are a relatively new, noninvasive treatment for GBM, which delivers low-intensity alternating electric fields that disrupt cancer cell division. At a recent scientific meeting organized by the Hong Kong Neurosurgical Society, Dr Alexander Grote of the Department of Neurosurgery, University Hospital of Marburg, Germany, and Professor Michael Lim of the Department of Neurosurgery, Stanford University, US, discussed the evolving role of TTFields in managing patients with GBM.

TTFields use in special GBM populations and potential combination with immunotherapy

14 Feb 2023

Glioblastoma: State-of-the-art therapeutic approaches

07 Jun 2022 by

Glioblastoma multiforme (GBM) is a highly malignant cancer with a median overall survival (OS) of approximately 1 year. At a recent webinar, experts shared keys to effective management of GBM and discussed state-of-the-art therapeutic approaches, including tumour-treating fields (TTFields), fluorescence-guided surgery, as well as intraoperative ultrasound and neuro-navigation integration.

Glioblastoma: State-of-the-art therapeutic approaches

07 Jun 2022

Tumour-treating fields – a versatile treatment modality for multiple cancer types

13 Dec 2021 by

Tumour-treating fields (TTFields) are a noninvasive cancer treatment modality, which first demonstrated clinical benefits in combination with chemotherapy in glioblastoma multiforme (GBM). At a webinar organized by the Hong Kong Cancer Therapy Society (HKCTS), experts discussed TTFields’ potential in other cancer types, including hepatocellular carcinoma (HCC) and pancreatic cancer, and the rationale for combining TTFields with immunotherapy.

Tumour-treating fields – a versatile treatment modality for multiple cancer types

13 Dec 2021

Use of tumour-treating fields for newly diagnosed glioblastoma multiforme

19 Oct 2021 by

A 60-year-old female complained of dizziness and weakness over the left side of her body (assessed strength, 4/5) when she presented in May 2019. CT scan of the brain revealed a mass measuring approximately 5 cm in the right temporal region and some compression of the ventricles. Craniotomy to excise the suspected malignant brain tumour was carried out in the same month, but was incomplete. The patient’s preoperative Eastern Cooperative Oncology Group (ECOG) performance status (PS) was 1.

Use of tumour-treating fields for newly diagnosed glioblastoma multiforme

19 Oct 2021

News & Updates

Filter by Specialty:

Specialty:

Rimegepant effective in triptan-exposed migraine patients

Rimegepant effective in triptan-exposed migraine patients

Management of adults with SMA: Practical considerations and treatment experiences

Management of adults with SMA: Practical considerations and treatment experiences

Fremanezumab effective in migraine prevention and depression management

Fremanezumab effective in migraine prevention and depression management

Use of radioligand therapy in a patient with metastatic GEP-NET

Use of radioligand therapy in a patient with metastatic GEP-NET

Use of low-dose edoxaban in a 99-year-old AF patient with comorbidities and comedications

Use of low-dose edoxaban in a 99-year-old AF patient with comorbidities and comedications

Protecting adults against herpes zoster: Why it matters

Protecting adults against herpes zoster: Why it matters

TTFields use in special GBM populations and potential combination with immunotherapy

TTFields use in special GBM populations and potential combination with immunotherapy

Glioblastoma: State-of-the-art therapeutic approaches

Glioblastoma: State-of-the-art therapeutic approaches

Tumour-treating fields – a versatile treatment modality for multiple cancer types

Tumour-treating fields – a versatile treatment modality for multiple cancer types

Use of tumour-treating fields for newly diagnosed glioblastoma multiforme

Use of tumour-treating fields for newly diagnosed glioblastoma multiforme